HistoSonics Evaluates Strategic Acquisition Offers Valued Over $2.5 Billion Amid Shift from IPO Plans

Registration: First Global Cardiovascular Conference| Latest Agenda

Call for Partners: 2025 Global Surgical Robotics Conference

On May 2, 2025, multiple U.S. media reports stated that,HistoSonics is evaluating multiple strategic investors, including Medtronic, GE Healthcare, and Johnson & Johnson.Potential Acquisition Offer, valued at over$2.5 billion (approximately 18.17 billion RMB)If this deal is reached, it may become one of the most closely watched platform-based M&A cases in the interventional oncology sector in recent years.

1. Overview of Acquisition Rumors: Who Wants to Acquire HistoSonics?

According to informed sources, the companies currently involved in negotiations or expressing interest include:

• Medtronic: Continuous expansion in the fields of tumor ablation and surgical robotics may enhance HistoSonics' minimally invasive tumor surgery portfolio.

• GE HealthCare: Starting with imaging systems, the real-time image-guided feature of Histotripsy has a natural synergy with GE's diagnostic equipment.

• Johnson & Johnson: Through its venture capital division JJDC, it has participated in HistoSonics' Series D financing round ($102 million). This acquisition, if it occurs, may represent a natural transition of capital.

In addition,Citigroup served as the financial advisor for this transaction., with the final bid expected to be received in the coming weeks.

The company had also considered the IPO route, but current macro market uncertainties have delayed the listing plan, leading to a prioritization of sale instead.

II. Valuation Logic: Why is an Ultrasound Ablation Platform Worth $2.5 Billion?

1. High Technical Threshold

Histotripsy belongs to a unique approach at the intersection of "non-thermal, non-ionizing, and non-invasive" triple attributes. While maintaining treatment precision, it causes minimal damage to healthy tissues. The complexity of the platform system is much higher than that of traditional thermal ablation devices.

2. Good clinical outcomes

• The 12-month local tumor control rate for liver cancer patients reached 90%, and it has received FDA de novo approval;

• Advancing the world's first Histotripsy treatment clinical trial for pancreatic cancer, targeting populations contraindicated for surgery;

• The solid and reliable clinical data serve as an important reference for investors to assess its potential.

3. Clear Expansion of Indications

Clinical trials for renal cancer, pancreatic cancer, and other solid tumors have been initiated or planned, showing potential for advancing into multiple high-value cancer types.

4. Platform Value Stands Out

The Edison system is not a one-time consumable product, but a systematic platform with capabilities such as AI image guidance, image navigation, and real-time feedback, possessing the potential to build a closed-loop of "preoperative evaluation-intraoperative control-postoperative monitoring."

Equipment Introduction:$100 Million! HistoSonics Completes Series D Financing for Ultrasound Tumor Treatment Platform

3. Potential Impact of the Acquisition on the Industry

If this M&A deal is finalized, it will mark that "platform-type interventional treatment equipment" is no longer an isolated island at the technological frontier, but will becomeThe Core Strategy for Large Enterprises to Build Closed-Loop Capabilities and Compete for the Future of Cancer Treatment。

4. Trends Worth Following Up

• Regulatory Pathway：The approval pace of indications such as pancreatic cancer and renal cell carcinoma will determine the subsequent market expansion speed；

• Reimbursement System Adaptation: Histotripsy, as a brand-new treatment pathway, needs to align with the logic of medical payment;

• Construction of Doctor Training System: The complexity of the equipment determines that widespread clinical adoption still requires time and educational promotion;

• Industry Chain Reaction: Once the giants complete the acquisition, it will stimulate more financing and expedite exits in the minimally invasive/non-thermal treatment track.